Healthia Introduces World’s First Remote Control Device for the Human Body

BOSTON--(BUSINESS WIRE)--Healthia SA will present a unique technology named GEMM that has been successfully used in Europe to treat terminal cancer patients, at the Medtech Insight’s upcoming In3 East Medical Technology Conference in Boston.

“It is possible to remotely control, intervene and modify cellular activities by applying specially modulated low power electromagnetic waves at the respective resonant frequency of the target molecules”

“It is possible to remotely control, intervene and modify cellular activities by applying specially modulated low power electromagnetic waves at the respective resonant frequency of the target molecules” says Seckiner Gorgun, MD, the inventor of the technology. “GEMM is a revolutionary device capable of selectively initiating or blocking any targeted chemical reaction in the cell. It acts like a remote control by giving precise orders to normalize malfunctioning biological processes.”

GEMM application simultaneously blocks both the glycolysis reaction and the activity of the malfunctioning glycoprotein sensors in the mitochondrial membranes of the cancer cells to prevent ATP production. Without producing energy the cancer cell cannot survive and immediately commits suicide. The targeted application has no effect on the normally functioning glycoprotein sensors in regular cells so they remain untouched.

GEMM Device has been used to treat terminal cancer patients in Italy since 1987. The very first patient Angela Vottari was suffering from a very malignant form of cancer named retroperitoneal leiomyosarcoma and was given no hope by her doctors. She had a 50 cm diameter inoperable tumor which adhered to vital organs and chemotherapy had no effect. The massive tumor shrank by almost 30% following the very first application and Mrs. Vottari has been healthily living since then without any recurrence, like many other patients treated with GEMM.

The mechanism is so precise that if the patient strictly adheres to the therapy, the response rate is almost 100%. In many patients symptoms disappear with the first weeks and by the end of the treatment generally lasting for two to three months, the aggressive tumors considerably shrink or completely vanish.

The CE Certified GEMM Device delivers low power radio waves through antenna located on top of the treatment beds. Daily sessions generally last around 30 minutes and no adverse events have been observed among the hundreds of treated patients over the last 20 years.

“GEMM is perhaps the biggest discovery in medical history” says Samil Ozavar, the President of Healthia SA based in Switzerland which holds exclusive rights to the technology. “Dr Gorgun has decided to go for a low profile, solo career so his marvelous discovery remained as a best kept secret which was only accessible to a network of patients who had significantly benefited from this technology.”

Healthia SA is looking to raise capital that will mainly be used for funding the much needed clinical trials to document the evident success of the GEMM Device in order to seek FDA approval. A detailed overview of the technology is accessible at www.gemm-therapy.com